III-01 Clémence Rigaux An approach for reducing the sample sizes of pediatric trials in Type 2 Diabetes Mellitus: longitudinal analysis versus standard analyses Thursday 09:55-11:20 |
III-02 Matthew Riggs M-EASE-1: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus Thursday 09:55-11:20 |
III-03 François Riglet Bayesian individual dynamic predictions of biomarkers and risk of event in joint modelling (with uncertainty): a comparison between Stan, Monolix and NONMEM Thursday 09:55-11:20 |
III-04 Christer Rimmler Evaluating the Influence of Cardiopulmonary Bypass on the Pharmacokinetics of Cefuroxime using PBPK and PopPK Models Thursday 09:55-11:20 |
III-05 Viktor Rognås Bounded Integer approach to model time-varying SOFA scores from patients with carbapenem resistant infections Thursday 09:55-11:20 |
III-06 Federico Romano Predictive performance of a parasite growth dynamics model for the evaluation of anti-malarial drugs: a case study with mefloquine Thursday 09:55-11:20 |
III-07 Daniel Röshammar Assessment of expected drug exposure relative maximum safety limits in early phase studies Thursday 09:55-11:20 |
III-08 Ryosuke Shimizu Quantitative systems pharmacology modeling of thrombopoiesis and platelet life-cycle, and application for thrombocytopenia Thursday 09:55-11:20 |
III-10 Tomohisa Saito The evaluation of a population pharmacokinetic model of Tofogliflozin with the data from healthy volunteers and T2DM patients Thursday 09:55-11:20 |
III-11 Louis Sandra A population pharmacokinetic model for propofol in (pre)term neonates and infants independently accounting for size, gestational age (GA) and postnatal age (PNA). Thursday 09:55-11:20 |
III-12 Marina Savelieva Modeling decline in cognition to decline in function in Alzheimer’s disease Thursday 09:55-11:20 |
III-13 Annika Schneider A PBPK approach for simulating the effect of liver cirrhosis on drug PK Thursday 09:55-11:20 |
III-14 Rik Schoemaker Performance of the SAEM and FOCEI algorithms in the open-source non-linear mixed effect modelling tool nlmixr Thursday 09:55-11:20 |
III-15 Jérémy Seurat Comparison of Phase I combination therapy designs by clinical trial simulations to evaluate early tumor shrinkage Thursday 09:55-11:20 |
III-16 Dmitry Shchelokov Physiologically based pharmacokinetic modeling of anti-PD-1 therapeutic antibodies Thursday 09:55-11:20 |
III-17 Soyoung Shin Novel population approach to establish in vitro-in vivo correlation for drugs with site-dependent absorption Thursday 09:55-11:20 |
III-18 Christian Siebel Development of an adaptive dosing approach for doxorubicin in paediatric cancer patients Thursday 09:55-11:20 |
III-19 Iryna Sihinevich Mathematical Modeling of Glucose Homeostasis in Morbidly Obese Diabetic Patients Undergoing Roux-en-Y Gastric Bypass Surgery: An IMI DIRECT Study Thursday 09:55-11:20 |
III-20 Florian Simon A generic PBPK model for predicting the impact of inflammation on midazolam pharmacokinetics Thursday 09:55-11:20 |
III-21 Noppaket Singkham Pharmacogenetics-Based Population Pharmacokinetic Analysis for Dosing Optimization of Ritonavir-Boosted Atazanavir in Thai adult HIV-Infected Patients Thursday 09:55-11:20 |
III-22 Jaydeep Sinha Extension of the Janmahasatian fat-free mass model to account for ethnicity-related bias Thursday 09:55-11:20 |
III-23 Erik Sjögren A PBPK Framework to Predict Drug Exposure in Malnourished Children Thursday 09:55-11:20 |
III-24 Eunjung Song Selection of optimal study design based on the bioequivalence simulation study in highly variable drugs Thursday 09:55-11:20 |
III-25 Elena Soto Population Pharmacokinetic (PopPK) Modelling and Simulation of Pregabalin to Support Dose Recommendation in Paediatric Patients 1 month to <4 years of Age with Partial Onset Seizures (POS) Thursday 09:55-11:20 |
III-26 Tomás Sou Translational PK and PKPD modelling for the analysis of preclinical in-vitro and in-vivo studies to predict efficacious human dose of apramycin Thursday 09:55-11:20 |
III-27 Viktoria Stachanow Does dried blood spot data enrich our understanding of hydrocortisone pharmacokinetics in paediatric patients with adrenal insufficiency? Thursday 09:55-11:20 |
III-28 Felix Stader Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving age-related changes in drug exposure in the elderly Thursday 09:55-11:20 |
III-29 Gabriel Stillemans Simultaneous population pharmacokinetic modeling of darunavir and cobicistat in a cohort of HIV patients Thursday 09:55-11:20 |
III-30 Mark Stroh Translation and Mechanistic Corroboration of the Preliminary Clinical Pharmacokinetics and Pharmacodynamics of a Masked, Tumor‑Activated anti-PD-L1 Antibody with Systems Pharmacology Thursday 09:55-11:20 |
III-31 Herbert Struemper Population Pharmacokinetics of Belimumab Administered Intravenously in Children with Systemic Lupus Erythematosus Thursday 09:55-11:20 |
III-32 Sabine Stuebler Systems biology model of the mucosal immune system Thursday 09:55-11:20 |
III-33 Suein Choi contribution of trough concentration data for the evaluation of multiple-dose pharmacokinetics Thursday 09:55-11:20 |
III-34 Jesper Sundell Pharmacokinetic variability of isoniazid, and its two major metabolites in patients co-infected with tuberculosis and HIV Thursday 09:55-11:20 |
III-35 Budi Octasari Susanto Translational Model-Informed Selection of Tuberculosis Drug Combination Regimens for Early Clinical Development Thursday 09:55-11:20 |
III-36 Hadi Taghvafard Modeling (a)symmetry of concentration-effect curves Thursday 09:55-11:20 |
III-37 Hiroyuki Takita The dynamics of pharmacological effects aimed at gut wall: A framework for a nested-target-within-enterocyte (NTWE) model that accounts for turnover of target and cell Thursday 09:55-11:20 |
III-38 Lénaïg Tanneau Evaluating potential link between liver enzyme abnormalities and bedaquiline exposure in multi-drug resistant tuberculosis patients Thursday 09:55-11:20 |
III-39 Joel Tarning Severe acute malnutrition results in lower exposure in children treated with artemether-lumefantrine for uncomplicated malaria Thursday 09:55-11:20 |
III-40 David Ternant Revisiting target-mediated elimination of therapeutic antibodies: the irreversible binding approximation Thursday 09:55-11:20 |
III-41 Mita Thapar Population pharmacokinetic analysis of MSB11022 following administration in healthy subjects and rheumatoid arthritis patients. Thursday 09:55-11:20 |
III-42 Anders Thorsted Model-based translation from piglets to healthy volunteers: Prediction of TNF-α and IL-6 time-courses in human endotoxin challenge studies Thursday 09:55-11:20 |
III-43 Tjokosela Tikiso A pooled analysis of abacavir pharmacokinetics in HIV-infected African children: the effect of age, malnutrition, and common concomitant co-medications. Thursday 09:55-11:20 |
III-44 Pauline Traynard New library of double absorptions PK models for the MonolixSuite, application to veralipride pharmacokinetics Thursday 09:55-11:20 |
III-45 Carlos Traynor Towards personalised medicine in Non-Small Cell Lung Cancer: design of a forecasting model of disease-progression to overall survival. Thursday 09:55-11:20 |
III-46 Iñaki F. Trocóniz A modelling platform for onco-immunological drugs in early drug development Thursday 09:55-11:20 |
III-47 Denise Feick Physiologically-based pharmacokinetic modeling of the CYP2C8 perpetrator trimethoprim Thursday 09:55-11:20 |
III-48 Sami Ullah Population pharmacokinetics of cefepime in critically ill patients with and without impaired renal function Thursday 09:55-11:20 |
III-49 Parth Upadhyay Exploring the Relationship Between Midazolam Concentrations And Level Of Sedation In Critically-Ill Mechanically Ventilated Children Using Markov Modelling Thursday 09:55-11:20 |
III-50 David Uster Predictive performance of population pharmacokinetic models for Bayesian forecasting of coagulation factor VIII in hemophilia A Thursday 09:55-11:20 |
III-51 Pavan Vaddady Application of Bayesian Methodology to Inform Imipenem/Relebactam Pediatric Study Design Thursday 09:55-11:20 |
III-52 Cristina Vaghi Population modeling of tumor growth curves, the reduced Gompertz model and prediction of the age of a tumor Thursday 09:55-11:20 |
III-53 Stijn van Beek Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients Thursday 09:55-11:20 |
III-54 Arthur Van De Vyver in vitro PK/PD modeling of immunological synapse-based tumor cell killing and immune activation to predict in vitro efficacy of T-Cell Bispecifics. Thursday 09:55-11:20 |
III-55 Louvina van der Laan Pharmacokinetics and drug-drug interactions of lamivudine and abacavir administered with antituberculosis drugs in HIV-infected children with multidrug-resistant tuberculosis Thursday 09:55-11:20 |
III-56 Jan-Stefan van der Walt A Population Pharmacokinetic Analysis to Explore the Effect of Hepatic Impairment on Abemaciclib Pharmacokinetics Thursday 09:55-11:20 |
III-57 Tamara van Donge Methadone dosing strategies in preterm neonates can be simplified Thursday 09:55-11:20 |
III-58 Rob van Wijk Nanoscale pharmacokinetics and pharmacodynamics of isoniazid treatment of tuberculosis in zebrafish larvae Thursday 09:55-11:20 |
III-59 Filippo Venezia Preclinical Pharmacokinetic/Pharmacodynamic modeling to evaluate combination efficacy and the modification effect of oncology compounds with anti-angiogenic drugs (Sunitinib, Axitinib) Thursday 09:55-11:20 |
III-60 Diego Vera Pharmacokinetic-Pharmacodynamic model for Acute Intermittent Porphyria in porphyric mice treated with a new recombinant PBGD protein Thursday 09:55-11:20 |
III-61 Luka Verrest Exploring variability in paromomycin pharmacokinetics in East African visceral leishmaniasis patients Thursday 09:55-11:20 |
III-62 Ludwig Vincent How to improve the accuracy of Drug-Drug Interaction risk prediction for Mechanism Based Inhibitors Thursday 09:55-11:20 |
III-63 Janet Wade Population PK analysis with full and reduced covariate models for Sym004, an antibody mixture targeting EGFR Thursday 09:55-11:20 |
III-64 Ulrika Wählby Hamrén Longitudinal FEV1 and exacerbation risk in COPD: Quantifying the association using joint modelling Thursday 09:55-11:20 |
III-65 Wenyi Wang Physiological Response to Endotoxin Infusion in the Piglet: Modelling of changes in hemodynamic outcomes Thursday 09:55-11:20 |
III-66 Shijun Wang Comparison of approaches for estimating covariate effects in full random effects models Thursday 09:55-11:20 |
III-67 Zhigang Wang A Pharmacokinetic-Pharmacodynamic model built on in vitro data predict the antibacterial effect of polymyxin B against Klebsiella pneumoniae in vivo Thursday 09:55-11:20 |
III-68 Linda Wanika Investigating the relationship between Lactate Dehydrogenase and the occurrence of Chronic Lower Respiratory Diseases Thursday 09:55-11:20 |
III-69 Shayne Watson Development and Evaluation of a Human Physiologically Based Pharmacokinetic Model to Assess a Mitigation Strategy for Risks Associated with Novel Monoclonal Antibodies Thursday 09:55-11:20 |
III-70 Sebastian Weber Qualifying drug dosing regimens in pediatrics using Gaussian Processes Thursday 09:55-11:20 |
III-71 Ferdinand Weinelt A joint pharmacokinetic model of piperacillin/tazobactam including mechanistic renal clearance in critically ill patients Thursday 09:55-11:20 |
III-72 Gustaf Wellhagen Modelling UACR as a clinical endpoint Thursday 09:55-11:20 |
III-73 Quirin Werthner Network-based mathematical modelling of HPV transmission and cervical cancer in Germany. Thursday 09:55-11:20 |
III-74 Sebastian Wicha TDMxR: an open-source package for model-based therapeutic drug monitoring in R Thursday 09:55-11:20 |
III-75 Mélanie Wilbaux Projecting MIW815 (ADU-S100) human tumor PK after intra-tumoral injection using a translational modeling approach combining pre-clinical and clinical data Thursday 09:55-11:20 |
III-76 Justin Wilkins Population Pharmacokinetics analysis of M5717, a novel antimalarial agent Thursday 09:55-11:20 |
III-77 Francis Williams Ojara Time-to-event analysis framework to evaluate the impact of paclitaxel exposure on peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first-line chemotherapy Thursday 09:55-11:20 |
III-78 Jan-Georg Wojtyniak Physiologically-based Pharmaokinetic Modelling of Metoprolol Drug-Drug-Gene Interactions with Paroxetine and CYP2D6 Thursday 09:55-11:20 |
III-79 Dan Wright Kinetic-pharmacodynamic models in the setting of non-linear drug elimination Thursday 09:55-11:20 |
III-80 Xia Li A Physiologically-Based Pharmacokinetic Model of Voriconazole Thursday 09:55-11:20 |
III-81 Rujia Xie Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Pediatric and Adult Patients with Invasive Fungal Infections Thursday 09:55-11:20 |
III-82 Estelle Yau A global sensitivity analysis of the Rodgers and Rowland equations predicting drug distribution in PBPK models Thursday 09:55-11:20 |
III-83 Anyue Yin Population pharmacokinetics and pharmacogenetics analysis of mitotane in adrenocortical carcinoma patients towards individualized dosing Thursday 09:55-11:20 |
III-84 Jinqiu Yin Pharmacokinetic-pharmacodynamic modeling of colistin against Pseudomonas aeruginosa-associated biofilm infections Thursday 09:55-11:20 |
III-85 Sirin Yonucu Explaining inter-species differences to anti-PDL1 cancer immunotherapy using a translational quantitative systems pharmacology approach Thursday 09:55-11:20 |
III-86 Jurij Aguiar Zdovc Population pharmacokinetic modeling of cisplatin in patients with small cell lung cancer using informative priors Thursday 09:55-11:20 |
III-87 Yang Zhang Ways to improve the efficiency of pharmacometric model implemented in R using deSovle – an example with a PK model for ADC Thursday 09:55-11:20 |
III-88 Chenyan Zhao Colistin to overcome resistance to ciprofloxacin - Quantifying combined effects of colistin and ciprofloxacin against four E. coli strains with different ciprofloxacin susceptibility in an in silico PKPD model Thursday 09:55-11:20 |
III-89 Xuan Zhou Model-Based Estimation of Probability of Pharmacological Success for CNS Compounds Thursday 09:55-11:20 |
III-90 Tom Zwart Population pharmacokinetics and limited sampling of iohexol as a renal function marker Thursday 09:55-11:20 |